NervGen Accounts Payable vs Net Tangible Assets Analysis
NGEN Stock | CAD 2.90 0.10 3.33% |
NervGen Pharma financial indicator trend analysis is infinitely more than just investigating NervGen Pharma Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NervGen Pharma Corp is a good investment. Please check the relationship between NervGen Pharma Accounts Payable and its Net Tangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Accounts Payable vs Net Tangible Assets
Accounts Payable vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NervGen Pharma Corp Accounts Payable account and Net Tangible Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between NervGen Pharma's Accounts Payable and Net Tangible Assets is 0.64. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of NervGen Pharma Corp, assuming nothing else is changed. The correlation between historical values of NervGen Pharma's Accounts Payable and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of NervGen Pharma Corp are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Accounts Payable i.e., NervGen Pharma's Accounts Payable and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | 0.64 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents NervGen Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NervGen Pharma Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from NervGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NervGen Pharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to drop to about 4.9 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year
NervGen Pharma fundamental ratios Correlations
Click cells to compare fundamentals
NervGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NervGen Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.8M | 6.7M | 17.9M | 23.9M | 13.2M | 11.3M | |
Other Current Liab | 172.4K | 583.3K | 725.5K | 8.1M | 11.7M | 12.3M | |
Total Current Liabilities | 923.9K | 755.1K | 1.1M | 10.2M | 15.1M | 15.9M | |
Total Stockholder Equity | 5.8M | 5.9M | 16.8M | 13.5M | (2.0M) | (1.9M) | |
Net Tangible Assets | 5.3M | 5.4M | 16.3M | 13.0M | 15.0M | 7.7M | |
Retained Earnings | (11.1M) | (22.3M) | (35.0M) | (55.8M) | (78.2M) | (74.2M) | |
Accounts Payable | 751.6K | 171.8K | 352.5K | 2.0M | 550.4K | 672.0K | |
Cash | 4.1M | 5.6M | 16.9M | 22.5M | 11.7M | 9.9M | |
Non Current Assets Total | 509.6K | 473.4K | 475.8K | 726.7K | 720.5K | 555.8K | |
Common Stock Shares Outstanding | 25.9M | 32.1M | 39.3M | 52.6M | 59.6M | 41.5M | |
Liabilities And Stockholders Equity | 6.8M | 6.7M | 17.9M | 23.9M | 27.5M | 28.8M | |
Total Liab | 923.9K | 755.1K | 1.1M | 10.4M | 15.2M | 16.0M | |
Net Invested Capital | 5.8M | 5.9M | 16.8M | 13.5M | (2.0M) | (1.9M) | |
Total Current Assets | 6.3M | 6.2M | 17.4M | 23.1M | 12.5M | 10.7M | |
Net Working Capital | 5.3M | 5.4M | 16.3M | 12.9M | (2.6M) | (2.5M) | |
Net Debt | (4.1M) | (5.6M) | (16.9M) | (22.2M) | (20.0M) | (19.0M) | |
Cash And Short Term Investments | 4.1M | 5.6M | 16.9M | 22.5M | 25.8M | 27.1M | |
Net Receivables | 122.5K | 62.6K | 64.0K | 27.0K | 250.2K | 262.7K | |
Other Current Assets | 2.0M | 540.8K | 427.6K | 669.9K | 602.9K | 594.4K | |
Other Stockholder Equity | 1.7M | 5.3M | 9.5M | 11.8M | 13.6M | 14.3M | |
Accumulated Other Comprehensive Income | 1.7M | 5.3M | 9.5M | 11.8M | 13.6M | 14.3M | |
Capital Stock | 15.3M | 22.9M | 42.4M | 57.4M | 58.9M | 36.8M | |
Intangible Assets | 509.6K | 471.4K | 473.2K | 431.4K | 520.8K | 393.9K | |
Common Stock | 15.3M | 22.9M | 42.4M | 57.4M | 66.0M | 69.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.